A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
Clinical trial NCT02193113 · COMPLETED
Trial details
- NCT number
- NCT02193113
- Sponsor
- KalVista Pharmaceuticals, Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-18
- Primary completion
- 2015-06-04
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.